Shudan Wang
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; text-indent: .5in; line-height: normal;"><span style="font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: 'Times New Roman';">Dr. Wang is an Attending Physician in the Division of Rheumatology at Montefiore Medical Center, and an Assistant Professor of Medicine at Albert Einstein College of Medicine. She is board certified in both internal medicine and rheumatology and currently sees patients at the Montefiore Westchester Practice at Taxter Road. Dr. Wang has an expertise in lupus and lupus related kidney disease. She is also skilled to see a wide range of other rheumatologic diseases, including but not limited to antiphospholipid syndrome, Sjogren’s syndrome, rheumatoid arthritis, <span style="color: black;">spondyloarthropathy</span> and psoriatic arthritis, vasculitis, myositis, polymyalgia rheumatica, scleroderma and osteoarthritis.</span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; text-indent: .5in; line-height: normal;"><span style="font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: 'Times New Roman';">Dr. Wang graduated from McGill University with a major in Physiology and Statistics in 2009. Dr. Wang received her medical degree from Rutgers New Jersey Medical School in 2013. She subsequently completed her internal medicine residency training at New York Presbyterian Hospital Cornell in 2016, followed by a fellowship in Rheumatology at New York University Hospital in 2018. Dr. Wang obtained a MS in clinical research from the Albert Einstein Clinical Research Training Program in 2021. </span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; text-indent: .5in; line-height: normal;"><span style="font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: 'Times New Roman';">Dr. Wang's research interest is in lupus, focused on the role of the complement system in lupus related kidney disease. Dr. Wang is supported by the NIH KL2 Mentored Clinical Research Scholar Grant and the Rheumatology Research Foundation K-Bridge Grant to investigate complement biomarkers in lupus nephritis using various translational approaches including immunohistochemistry, urine proteomics and single cell RNA sequencing. Dr. Wang has experience working with large cohorts and databases, recruiting patients for the Einstein Rheumatic Disease Registry and serve as sub-investigator for lupus clinical trials. She has published first author papers in prestigious journals, presented her academic work at national meetings and served on NIH and CDC study sections. She was recognized by American College of Rheumatology as a Distinguished Fellow nationally for translational research and clinical excellence in 2018.</span></p>
<p class="MsoNormal" style="mso-outline-level: 1;"><strong><span style="font-family: 'Arial',sans-serif;">Wang Shudan</span></strong><span style="font-family: 'Arial',sans-serif;">, Wu M, Chiriboga L, Zeck B, Goilav B, Wang Shuwei, Jimenez-Londono A, </span><span style="font-family: 'Arial',sans-serif;">Putterman C, Schwartz D, Pullman J, Broder A, HM Belmont. Membrane Attack Complex (MAC) Deposition in Renal Tubules is Associated with Interstitial Fibrosis/Tubular Atrophy: A Pilot Study. <em>Lupus Science & Medicine. </em>2022 Jan; 9(1). </span></p>
<p class="MsoNormal" style="mso-outline-level: 1;"><span style="font-family: 'Arial',sans-serif;">Tagoe, CE, Wang W, <strong>Wang S</strong>, Barbour K. Association of anti-thyroid antibodies with radiographic knee osteoarthritis and chondrocalcinosis: a NHANES III study. <em>Therapeutic Advances in Musculoskeletal Disease. </em>2021 Aug 4; 13. </span></p>
<p class="MsoNormal" style="mso-outline-level: 1;"><span style="font-family: 'Arial',sans-serif;">Guerrero, MS, Londono, A, Dobrowolski C, Mowrey WB, Goilav B, <strong>Wang S</strong>, Broder A. Systemic Lupus Erythematosus Activity and Hydroxychloroquine Use Before and After End-Stage Renal Disease. <em>BMC Nephrology</em>. 2020 Oct 28; 21(1): 450.</span></p>
<p class="MsoNormal"><strong style="mso-bidi-font-weight: normal;"><span style="font-family: 'Arial',sans-serif;">Wang S, </span></strong><span style="font-family: 'Arial',sans-serif;">Wu M, Pillinger MH, Krasnokutsky, S, and Barbour K. The Association between Asymptomatic Hyperuricemia and Knee Osteoarthritis: Data from Third National Health and Nutrition Examination Survey. <a title="Osteoarthritis and cartilage." href="https://www.ncbi.nlm.nih.gov/pubmed/?term=The+Association+between+Asymp… class="highlight"><em><span style="color: windowtext; text-decoration: none; text-underline: none;">Osteoarthritis</span></em></span><em> Cartilage.</em></a> 2019 Sep;27(9):1301-1308. </span></p>
<p class="MsoNormal"><strong style="mso-bidi-font-weight: normal;"><span style="font-family: 'Arial',sans-serif; color: black;">Wang S, </span></strong><span style="font-family: 'Arial',sans-serif; color: black;">Wu M, Chiriboga L, Zeck B, HM Belmont. Membrane Attack Complex (MAC) Deposition in Lupus Nephritis is Associated with Hypertension and Poor Clinical Response to Treatment. <em style="mso-bidi-font-style: normal;">Semin Arthritis Rheum. 2018; 48(2): 256-262.</em><span style="mso-spacerun: yes;"> </span></span></p>
<p class="MsoNormal"><strong style="mso-bidi-font-weight: normal;"><span style="font-family: 'Arial',sans-serif; color: black;">Wang S, </span></strong><span style="font-family: 'Arial',sans-serif; color: black;">Broder N, Marchetta P, Nowatzky J. Myelodysplastic syndrome presenting as a Behcet’s like syndrome with aortitis. <em style="mso-bidi-font-style: normal;">BMJ Case Rep. 2018 March 15. </em><span style="mso-spacerun: yes;"> </span></span></p>
<p class="MsoNormal"><span style="font-family: 'Arial',sans-serif; color: black;">Oshima-Takane Y, <strong style="mso-bidi-font-weight: normal;">Wang S</strong>, Takane M and Takane, Y. T</span><span style="font-family: 'Arial',sans-serif;">he Acquisition of Personal Pronouns in English: Neural Network Stimulations. S<em style="mso-bidi-font-style: normal;">tudies in Language Sciences. 2014, Jan: 13 (53-69).</em></span></p>
<p class="MsoNormal" style="margin-right: 24.0pt;"><span style="font-family: 'Arial',sans-serif;">Sleat DE, Ding L, <strong style="mso-bidi-font-weight: normal;">Wang S, </strong>Zhao C, Wang Y, Zheng H, Moore DF, Sims KB, Lobel P<strong style="mso-bidi-font-weight: normal;">. </strong>Mass spectrometry-based protein profiling to determine the cause of lysosomal storage disease of unknown etiology. <em style="mso-bidi-font-style: normal;">Mole Cell Proteomics</em>. <em style="mso-bidi-font-style: normal;">2009 Jul; 8(7): 1708-18.</em> </span></p>
<p class="MsoNormal" style="margin-right: 24.0pt; text-indent: -.25in;"><strong style="mso-bidi-font-weight: normal;"><span style="mso-bidi-font-family: Arial;"> </span></strong></p>
Victoria Vapnyar
Kristine E. Torres-Lockhart
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Kristine Torres-Lockhart, MD, FASAM is an Assistant Professor of Medicine in the Division of General Internal Medicine and Department of Psychiatry and Behavioral Sciences at Montefiore Medical Center and the Albert Einstein College of Medicine, as well as the founding director of the Addiction Consult Service at Montefiore's Weiler Hospital. She is Program Director of the Addiction Medicine Fellowship and Co-Director of the Addiction Medicine rotation for medical trainees. An addiction medicine and internal medicine physician, she leads the development and implementation of health system interventions to improve substance use disorder (SUD) care in acute care settings and transitions of care to post-acute and ambulatory care settings.</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><br />Dr. Torres-Lockhart provides SUD treatment, HIV/AIDS care, hepatitis C treatment, and general internal medicine care at several sites across Montefiore Medical Center, including a community health care center. She also actively teaches and supervises medical students, residents, and fellows. She is double board certified in addiction medicine and internal medicine and credentialed as an HIV specialist by the American Academy of HIV Medicine. <br /><br />Dr. Torres-Lockhart completed her fellowship training in addiction medicine at Montefiore Medical Center. Prior to arriving at Montefiore, she completed her residency training in internal medicine and primary care at Brigham and Women’s Hospital in Boston, MA, where she also served as primary care chief medicine resident at the West Roxbury and Jamaica Plain Veterans Affairs Medical Centers. She received her undergraduate degree from Dartmouth College and her medical degree from the Geisel School of Medicine at Dartmouth. She is the PI for a HRSA training grant and co-PI for an OASAS training grant to lead the development of educational opportunities in building the addiction medicine workforce. She currently serves on the Board of Directors for the New York Society of Addiction Medicine previously as Communication Chair and now as Secretary. </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Singh-Tan, S., <strong>Torres-Lockhart, K.</strong>, Jakubowski, A., Lu, T., Starrels, J., De Lima, P., Arnsten, J., Nahvi, S., Southern, W. (2023). Addiction Consult Service and Inpatient Outcomes Among Patients with Alcohol Use Disorder. /J Gen Intern Med/, 1-8. doi:10.1007/s11606-023-08202-7</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Jakukowski, A., Singh-Tan, S., <strong>Torres-Lockhart, K</strong>., Nahvi, S., Stein, M., Fox, A. D., & Lu, T. (2023). Hospital-based clinicians lack knowledge and comfort in initiating medications for opioid use disorder: opportunities for training innovation. /Addict Sci Clin Pract, 18/(1), 31. doi:10.1186/s13722-023-00386-x</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Calcaterra, S. L., Bottner, R., Martin, M., Englander, H., Weinstein, Z. M., Weimer, M. B., Lambert, E., Ronan, M., Huerta, S., Zaman, T., Ullal, M., Peterkin, A., <strong>Torres-Lockhart, K.</strong>, Buresh, M., O’Brien, M., Synder, H., Herzig, S. J. (2022). Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines. /J Hosp Med, 17(9),/679-692/./doi:10.1002/jhm.12908</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"><strong>Torres-Lockhart, K.</strong> E., Lu, T. Y., Weimer, M. B., Stein, M. R., & Cunningham, C. O. (2022). Clinical Management of Opioid Withdrawal. /Addiction, 117/(9), 2540-2550. doi:10.1111/add.15818</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Cunningham, C. O., Khalid, L., Deng, Y., <strong>Torres-Lockhart, K.</strong>, Masyukova, M., Thomas, S., Zhang, C., Lu, T. (2022). A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic. /J Subst Abuse Treat, 135/, 108641. doi:10.1016/j.jsat.2021.108641</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Joseph, G., <strong>Torres-Lockhart, K.</strong>, Stein, M. R., Mund, P. A., & Nahvi, S. (2021). Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19. /J Subst Abuse Treat, 122/, 108219. doi:10.1016/j.jsat.2020.108219</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">He, L., <strong>Torres-Lockhart, K.</strong>, Forster, N., Ramakrishnan, S., Greninger, P., Garnett, M. J., McDermott, U., Rothenberg, S.M., Benes, C.H., Ellisen, L. W. (2013). Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. /Cancer Discov, 3/(3), 324-337. doi:10.1158/2159-8290.CD-12-0417</p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;"> </p>
<p class="MsoNormal" style="margin: 0in; font-size: medium; font-family: Calibri, sans-serif;">Ibrahim, Y. H., Garcia-Garcia, C., Serra, V., He, L., <strong>Torres-Lockhart, K</strong>., Prat, A., Anton, P., Cozar, P., Guzman, M., Grueso, J., Rodriguez, O., Calvo, M.T., Aura, C., Diez, O., Rubio, I.T., Perez, J., Rodon, J., Cortes, J., Ellisen, L.W., Scaltriti, M., Baselga, J. (2012). PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. /Cancer Discov, 2/(11), 1036-1047. doi:10.1158/2159-8290.CD-11-0348</p>
<p>Kristine E. Torres-Lockhart, MD, FASAM, is Director, Addiction Medicine Fellowship Program at Montefiore Einstein, Founding Director, Addiction Consult Service at Weiler Hospital and Assistant Professor, General Internal Medicine and Psychiatry and Behavioral Sciences at our Albert Einstein College of Medicine. Dr. Torres-Lockhart is a general internist, primary care provider and addiction medicine specialist. She focuses on caring for people who use substances and people with substance use disorders, providing care in hospital settings and in outpatient clinics.</p><p>After obtaining her Bachelor of Arts in neuroscience from Dartmouth College in 2010, Dr. Torres-Lockhart earned her Doctor of Medicine at the Geisel School of Medicine at Dartmouth in 2016. She completed an internship and residency in internal medicine and primary care at Brigham and Women’s Hospital in 2019. Following this, Dr. Torres-Lockhart completed a fellowship in addiction medicine at Montefiore Einstein in 2020.</p><p>Dr. Torres-Lockhart's research focuses on evidence-based and harm-reduction-oriented strategies for addressing substance use disorder care in acute care settings, integration of addiction medicine into medical education and optimizing transitions of care for people who use drugs. She has been principal investigator and co-investigator on funded research projects and her work has been published in numerous peer-reviewed publications. Dr. Torres-Lockhart has also shared her work through numerous invited presentations, abstracts and poster presentations. She is a reviewer for scientific journals, including Addiction Science and Clinical Practice, the Journal of Addiction Medicine, the Journal of Substance Abuse Treatment and the Journal of Hospital Medicine.</p><p>Dr. Torres-Lockhart is board certified by the American Board of Internal Medicine and the American Board of Preventive Medicine with certification in Addiction Medicine. She is a Fellow of the American Society of Addiction Medicine, board member of the New York Society of Addiction Medicine and member of the Association for Multidisciplinary Education and Research in Substance Use and Addiction. In 2022, Dr. Torres-Lockhart received the President’s Award at the New York Society of Addiction Medicine’s Annual Conference. In 2023, she received the Quality Improvement Champion honor at the United Hospital Fund's Tribute to Excellence in Health Care and was a Rising Star Nominee for the Department of Medicine’s Physician Recognition Awards at Montefiore Einstein.</p>
Peter L. Tenore
Dr. Tenore is a Medical Director in the Division of Substance Abuse and is a wekk known figure in this field, having published in several journals and providing education in substance abuse to local and state agencies. He is an advisor to the New York State Ofice of Alcoholism and Substance Abuse Services and the federal Center for Substance Abuse Treatment. He is certified in Internal Medicine and by examination in Addiction Medicine and a New York State HIV Provider. His particular interests are management of cocaine and other addictions as well as providing hepatitis C and HIV treatment in the methadone clinic setting.
DINO-VAMP: A Helpful Acronym in Determining Optimal Methadone Dosing and Brief review of Dosing Literature, Journal of Maintenance in the Addictions, Vol.2(4).
Guidance On Optimal Methadone Dosing, Addiction Treatment Forum, Vol.12 (2).
Methadone:A Medical Model in "Innovations in Substance Abuse Treatment and Policy," Yale University Center for Interdisciplinary Research, Yale Publicatinos, New Haven, CT.
Three Oral Formulations of Methadone: A Clinical and Pharmacodynamic Comparison, Journal of Substance Abuse Treatment, Vol. 17(3), Gourevitch, Hartell, Tenore, et al.
Clement E. Tagoe
<p>Dr. Clement Tagoe obtained his medical degree from the University of Ghana Medical School, Ghana, and a PhD in biochemistry from the University of Leeds, UK. His basic science research interests included the study of the role of annexins in cell function and rheumatic diseases, and subsequently the mechanisms of disease in transthyretin amyloidosis using several animal models of transthyretin amyloidosis. His clinical work in the area of transthyretin amyloidosis has greatly illuminated our understanding of the form of amyloidosis associated with the Transthyretin V122I (pV142I) mutation, which is found in about 3 to 4% of African Americans. His current work focuses on the role of autoimmune diseases in fibromyalgia and chronic widespread pain, and in particular the association of these syndromes with autoimmune thyroid disease (AITD). His work also explores the other musculoskeletal and rheumatic manifestations of autoimmune thyroid disease, including the association with peripheral osteoarthritis and spinal osteoarthritis. These autoimmune syndromes can occur in the absence of thyroid dysfunction and are of particular interest to physicians and patients because AITD is by far the commonest autoimmune disease.</p>
<p class="MsoNormal"><strong>Selected Bibliography</strong></p>
<p class="MsoNormal">1. Clement E. Tagoe, Tejas Sheth, Eugeniya Golub, Karen Sorensen (2019) Rheumatic associations of autoimmune thyroid disease: a systematic review Clin Rheumatol. 2019 Jul;38(7):1801-1809., (1-9) DOI: 10.1007/s10067-019-04498-1</p>
<p class="MsoNormal">2. Kavisha Patel, Clement Tagoe, Phyllis Bieri, Karen Weidenheim & James M. Tauras (2018): A case of transthyretin amyloidosis with myopathy, neuropathy, and cardiomyopathy resulting from an exceedingly rare mutation transthyretin Ala120Ser (c.418G > T, p.Ala140Ser), Amyloid, DOI: 10.1080/13506129.2018.1491398</p>
<p class="MsoNormal">3. Daniel R. Jacobson, Alice A. Alexander, Clement Tagoe, W. Timothy Garvey, Scott M.</p>
<p class="MsoNormal">Williams, Sara Tishkoff, David Modiano, Sodiomon Bienvenu Sirima, Issa Kalidi, Toure A, & Joel N. Buxbaum. The Prevalence and Distribution of the Amyloidogenic Transthyretin (TTR) V122I Allele in Africa Molecular Genetics & Genomic Medicine Epub 14 July, 2016 DOI: 10.1002/mgg3.231</p>
<p class="MsoNormal">4. Asha Shrestha, Hillel W. Cohen, Clement E. Tagoe. Association of Autoimmune Thyroid Disease With A Higher Frequency Of Spinal Degenerative Disc Disease Clin Exp Rheumatol. 2016 Mar-Apr;34(2):296-302. Epub 2016 Feb 9. PMID: 26885680</p>
<p class="MsoNormal">5. Tagoe CE, Zezon A, Khattri S. Rheumatic manifestations of autoimmune thyroid disease: the other autoimmune disease. J Rheumatol. 2012 Jun;39(6):1125-9. Epub 2012 Apr 15.</p>
<p> </p>
<p class="MsoNormal"> </p>
<p> </p>
Asli S. Sucu
Melissa R. Stein
<p><strong>Current Investigations</strong></p>
<ol start="1" style=" margin-bottom: 0in;" type="1">
<li>Development of an Objective Structured Clinical Examination (OSCE) in Substance Abuse</li>
</ol>
<p> </p>
Martina Stehlikova
<p>In-patient internal medicine with a special interest in hematology. Anemia, thrombocytopenia and coagulopathy in hospitalised patients.</p>